tbuckley/cabot-search huggingface dataset:
THU0089 A Patient Reported Outcome Measures-Based Composite Index (RAPID3) for the Assessment of Disease Activity in Ankylosing Spondylitis
Authors: M. Cinar, S. Yilmaz, F.I. Cinar, S.S. Koca, H. Erdem, S. Pay, A. Dinc, Y. Yazici, I. Simsek
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There are disease-specific activity measures for almost each rheumatic disease. Disease-specific questionnaires may be optimal for clinical trials and other research studies, but it is not feasible to have patients complete different self-report questionnaires in busy clinical settings. A single questionnaire regarding to disease activity for all rheumatic diseases may present advantages to introduce quantitative measurement into routine care. Recently, routine assessment of patient index data 3 (RAPID3) which is based on 3 multi-dimensional health assessment questionnaire (MDHAQ) components, including patient function, pain, and patient global assessment, is speculated to be a candidate index for most of the rheumatic diseases. <h3>Objectives</h3> To evaluate correlation of RAPID3 with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and AS Disease Activity Score (ASDAS). <h3>Methods</h3> This single-center, cross-sectional study was performed in a rheumatology department at a tertiary-care hospital in Turkey between May 2011 and September 2013. We included 341 consecutive AS patients who met the modified New York classification criteria. All patients completed BASDAI, and MDHAQ at each visit, and their physicians completed physician global assessment. ASDAS scores were calculated using defined formulas. Proposed RAPID3 severity categories were compared to BASDAI and ASDAS categories. Spearman9s rho correlation test and kappa statistics were used to analyze statistical significance. <h3>Results</h3> The median age of AS patients was 34.0 (21.0-69.0) years and the median disease duration 10.0 (2.0-35.0) years; 273 patients (80.1%) were male. Median scores for RAPID3, BASDAI, ASDAS-CRP, and ASDAS-ESR, were 13.0 (0.0-27.3), 4.7 (0.0-9.7), 3.0 (0.4-5.8), 2.5 (0.5-6.3), respectively. RAPID3 was strongly correlated with BASDAI, and ASDAS-ESR (r=0.842, r=0.815; p&lt;0.001, respectively). Among the 209 patients with high disease activity according to BASDAI, 83.3% had high or moderate severity according to RAPID3. The kappa statistic for agreement of RAPID3 with BASDAI was 0.693 (p&lt;0.001). Among the 133 patients with moderate, high, and very high disease activity on ASDAS-CRP, 91.7% had high or moderate severity according to RAPID3. The kappa statistic for agreement of RAPID3 with ASDAS-CRP was 0.548 (p&lt;0.001). <h3>Conclusions</h3> RAPID3 is as informative as BASDAI and ASDAS in our cohort of AS patients. We therefore suggest that RAPID3 may be used to assess, monitor, and document patient status quantitatively in AS patients, as part of routine care. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1940
Managed Care: Impact on Patients
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Managed Care: Impact on Patients Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 12, 21 June 1995, Page 865, https://doi.org/10.1093/jnci/87.12.865 Published: 21 June 1995
The Relative Function of Damaged Kidneys in Children Does Not Deteriorate Further at 3-Year Follow-up
Authors: Amy Whittaker, Maria Moon, Grant Mitchell, Bruce McBride, Monica A. Rossleigh, Andrew R. Rosenberg
Journal: Clinical Nuclear Medicine (2014)

It is thought that the function of a damaged kidney will deteriorate further with time because of impaired maturation and compensatory hyperfiltration. The aim of this study was to determine changes in relative renal function (RRF) over time in children with vesicoureteric reflux (VUR) and/or urinary tract infection (UTI) where the unilaterally scarred kidney was found to contribute 30% or less to overall function.Children who met the inclusion criteria and had multiple radionuclide studies during a 12-year period were identified, and RRF was compared.Twenty-seven boys and 3 girls with a median age of 0.8 years (0.08-13.05 years) were included. Eight patients had unilateral VUR, 21 patients had bilateral VUR, and 1 patient had UTIs without VUR. Twenty-one patients underwent reimplantation surgery, and 9 were managed conservatively.At a mean follow-up of 2.64 years (0.26-6.77 years), there was a nonsignificant mean decrease in RRF from 19% (11%-28%) to 18% (9%-29%). The mean change in renal function was not affected by the severity of the initial RRF.In the medium term, there is no deterioration of RRF of unilaterally severely damaged kidneys associated with either VUR or UTI managed either surgically or conservatively. Boys are at a much greater risk of severe reflux nephropathy.
AB0114 Semaphorin3a and semaphorin4d in rheumatoid arthritis.
Authors: Y. Yoshida, S. Kang, A. Morishima, N. Akihiko, Y. Hishitani, Y. Maeda, M. Nishide, M. Hamano, K. Morimoto, T. Hirano, Y. Shima, M. Narazaki, T. Tanaka, A. Ogata, A. Kumanogoh
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Semaphorins are involved in a wide range of biological processes, including neuronal axon guidance, angiogenesis, immune modulation and osteogenesis (1, 2). Semaphorin 3A (Sema3A) suppress osteoclast function and increase osteoblast function (3). Semaphorin 4D (Sema4D), which is expressed by osteoclast, suppress osteoblast function (4). Sema4D and 3A might be key mediators of osteoimmunology in rheumatoid arthritis (RA), which have immune activation associated bone destruction. <h3>Objectives</h3> To determine the pathogenic role of Sema3A and Sema4D in RA, we evaluated the serum level of Sema3A and Sema4D in RA patients. <h3>Methods</h3> Concentrations of Sema3A and Sema4D in 102 RA patients and 26 normal controls were measured by ELISA (Mybiosource). <h3>Results</h3> The serum concentrations of Sema4D in RA patients and normal controls were 11.16±8.49 and 5.87±3.10ng/ml respectively (p&lt;0.00001). The serum concentrations of Sema 3A in RA patients and normal controls were 8.97±3.71 and 6.65±3.75 ng/ml respectively (p&lt;0.01). Serum concentrations of Sema4D in RA patients were associated with disease activity (DAS28 r=0.38, p&lt;0.01, CRP r=0.34, p&lt;0.01), rheumatoid factor (RF) (r=0.33, p&lt;0.01) and marker of bone metabolism (urine deoxypyridinoline r=0.32 p&lt;0.05). However serum Sema3A didn't associated with disease activity and marker of bone metabolism. <h3>Image/graph</h3> <h3>Conclusions</h3> Serum concentration of Sema3A and Sema4D were elevated in RA patients. In particular Sema4D showed association with disease activity, RF, and marker of bone metabolism. Semaphorins may play an important role in RA by immune activation, angiogenesis, increasing primary afferent sensory fibers with sympathetic nerve fiber repulsion in synovium, and bone destruction in joints. <h3>References</h3> Kumanogoh A et al. Immunity. 2000;13:621-31. Takamatsu H et al. Nat Immunol. 2010;11:594-600. Negishi-Koga T et al. Nat Med. 2011;17:1473-80. Hayashi M et al. Nature. 2012;485:69-74. <h3>Disclosure of Interest</h3> None Declared
Prostate Cancer Comes Out of the Closed
Authors: A. Shane
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Prostate Cancer Comes Out of the Closed Get access Alice Shane Alice Shane Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 8, 17 April 1991, Page 536, https://doi.org/10.1093/jnci/83.8.536 Published: 17 April 1991
Thromboxane Synthase and Organ Preference for Metastases
Authors: Amin A. Nanji
Journal: New England Journal of Medicine (1993)

To the Editor: Studies of the metastatic behavior of cancer suggest that one of the factors influencing the site at which tumor cells lodge is the presence of a special “soil” that favors the survival and growth of these tumor cells. A variety of hormonal and growth factors have been shown to influence the expansion of a metastatic colony. One such factor is evidence that tumor cells and platelets interact to promote metastasis1. Tumor cells can activate platelets that undergo the release reaction and make available as yet unidentified mediators that promote tumor growth. In some models, the degree . . .
Role of EUS-guided FNA in the Diagnosis of Solid Pancreatic Lesions. A Single Center Experience
Authors: J Talapaneni, S Singh, S Puli, M Oropeza-vail, M Olyaee
Journal: Endoscopy (2006)

Introduction: Mass lesions of the pancreas can be malignant or benign, which is often difficult to differentiate. Differentiating these tumors is essential for optimal management and outcome. The purpose of this study was to retrospectively evaluate the accuracy of EUS-FNA in cytologic diagnosis of pancreatic solid lesions. Methods: A retrospective review was done to identify patients who underwent EUS from year 2002 to year 2005 for an abnormal pancreatic imaging (mass lesion, fullness or prominent head of pancreas). EUS-FNA was performed using 22-gauge needle. Onsite cytopatholgist was available to determine the adequacy of the sample. Results: 320 patients underwent EUS for an abnormal pancreatic image. Out of these, 123 patients had a solid pancreatic lesion and had EUS-FNA performed. The cytopathology results of EUS-FNA are as shown in table 1. Surgical confirmation of pancreatic adenocarcinoma was available in 41 out of 72 patients. Follow up of patients with atypical cytology on subsequent surgery revealed pancreatic malignancy in 4 patients. The sensitivity, specificity, positive predictive value and negative predictive value of EUS-FNA in the diagnosis of solid pancreatic tumors at our center is 89.13%, 100%, 100% and 27.5% respectively.
Blood Groups, Myocardial Infarction and Angina Pectoris among 10,000 Adult Males
Authors: Jack H. Medalie, Cyril Levene, Cheri Papier, Uri Goldbourt, F. Dreyfuss, Dvora Oron, Henry Neufeld, Egon Riss
Journal: New England Journal of Medicine (1971)

A five-year prospective investigation of 10,000 Israeli male government employees 40 years of age and over was conducted as part of the Israeli Ischemic Heart Disease Project. The six areas of birth represented were Eastern Europe, Central Europe, Southeastern Europe, Israel, Asia, and North Africa. Subjects with blood Groups A1, B, and A1B tended to have higher incidence rates of myocardial infarction than those with other blood groups. High rates were also noted in A1 and B subjects for angina pectoris. Subjects in blood Group O tended to have lower rates of infarction and angina pectoris than those of other groups, but the differences were not significant. Among the Rhesus, MN, Kell, Duffy and Kidd blood groups, subjects with Kidd negative (JKa-) had the highest rates for both myocardial infarction and angina pectoris. When this group was added to the ABO system, the combinations of A1Jka-, BJka- and, particularly, A1BJka-, had very high incidence rates.
Submucosal tunnel dissection through the pyloric ring for removal of a sessile duodenal adenoma adjacent to a scar
Authors: P. Jin, J. Sheng, A. Li, K. Fu
Journal: Endoscopy (2013)

Endoscopic submucosal dissection (ESD) for duodenal neoplasms is generally difficult because of the thin wall and narrow lumen of the duodenum [1]. A scar near the neoplasm due to chronic ulcer or biopsies often makes the situation more formidable. We report the case of a duodenal adenoma in a 52-year-old man. Esophagogastroduodenoscopy (EGD) had shown a sessile polyp on the front wall of the duodenal bulb, with an estimated size of 4 × 3 cm ([Fig. 1]). The lesion extended to the pyloric canal, and there was a peptic ulcer scar near the polyp. Magnifying narrowband imaging showed a tubular pit pattern and irregular villous structure ([Fig. 2]). Biopsy demonstrated that the polyp was a tubulovillous adenoma with moderate dysplasia. ESD was employed for its removal. Sodium hyaluronate was used for submucosal injection, and a Dual-Knife (Olympus Corp., Tokyo, Japan) was used for mucosal resection and submucosal dissection ([Video 1]).
414 THE SEROSTATUS OF HEPATITIS B AFTER 50 MONTHS FOLLOWUP AMONG 313 HEPATITIS B SERONEGATIVE YOUNG ADULTS BORN AFTER NEONATAL HEPATITIS B VACCINATION ERA
Authors: C.-F. Jan, Y.-C. Chien, K.-C. Huang, M.-H. Lin, C.-J. Chen
Journal: Journal of Hepatology (2013)
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Authors: Renée E. Poupon, Beverley Balkau, Eveline Eschwège, Raoul Poupon
Journal: New England Journal of Medicine (1991)

In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of potentially toxic endogenous bile acids. Preliminary work suggests that the administration of ursodiol (also called ursodeoxycholic acid), a hydrophilic bile acid without hepatotoxicity, leads to improvement in the condition of patients with primary biliary cirrhosis.
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
Authors: Edward M. Connor, Rhoda S. Sperling, Richard Gelber, Pavel Kiselev, Gwendolyn Scott, Mary Jo O'Sullivan, Russell VanDyke, Mohammed Bey, William Shearer, Robert L. Jacobson, Eleanor Jimenez, Edward O'Neill, Brigitte Bazin, Jean-Francois Delfraissy, Mary Culnane, Robert Coombs, Mary Elkins, Jack Moye, Pamela Stratton, James Balsley
Journal: New England Journal of Medicine (1994)

Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.
ASSOCIATIONS OF ABDOMINAL OBESITY AND NEW ONSET ATRIAL FIBRILLATION IN GENERAL POPULATION: A NATIONWIDE COHORT STUDY IN KOREA
Authors: Yongsoo Baek, Pil-Sung Yang, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung
Journal: Journal of the American College of Cardiology (2016)
Abstract 3818: CD11c+CD123+ human myeloid dendritic cells generated using IL4, IL13 and IL3 show characteristics of myeloid derived suppressor cells
Authors: Jeremy V. Edwards, Hua Zhang, Crystal L. Mackall
Journal: Cancer Research (2010)

Abstract Dendritic cells (DCs) are critical for initiation of adaptive immune responses, but they also play important roles in self-tolerance, and in tumor bearing hosts, some DC subsets may contribute to immune evasion. Myeloid derived suppressor cells (MDSC) are also important mediators of tumor immune evasion. The relationship between myeloid DC and MDSCs in humans remains unclear. Human myeloid DCs are defined as CD11c+CD123-, although some have reported dim CD123 expression on human myeloid DCs. We describe a CD11c+CD123+ myeloid DC subset that shows characteristics of a MDSC. Monocytes elutriated from normal donors were incubated for 48hr with IL4 ± IL13 ± IL3. Monocytes cultured with all three cytokines acquired strong expression of both CD123 and CD11c, with 79.5% of cells CD123+CD11c+. CD11c+CD123+ cells demonstrated over-expression of both arginase and iNOS by flow cytometry and/or real-time PCR in comparison to myeloid derived DCs generated with IL4, GM-CSF and LPS (mean fluorescence intensity of arginase in the IL4, IL13 and IL3 generated cells of 5973 vs. 1961 in IL4, GM-CSF and LPS generated cells). CD11c+CD123+ DCs also coexpress IL-4Rα and IL7Rα, characteristics of MDSC and regulatory DC subsets respectively. IL3 appears to be a potent inducer of CD123 expression on CD11c+ DCs, since myeloid DCs generated with only IL4 and IL13, in combination or separately, showed a less pronounced phenotype (38-52.7% CD11c+CD123+). Moreover, CD123 expression on myeloid DCs appears to be a marker for arginase production since CD123+ cells within the IL4, IL13 and IL3 cultures show higher arginase expression than CD123- cells within the same cultures. Functional studies are ongoing. In conclusion, human myeloid DCs generated by incubating monocytes with IL4, IL13 and IL3 have a novel CD11c+CD123+ phenotype and show characteristics of myeloid derived suppressor cells, raising the prospect that IL3 plays an important role in generating myeloid derived suppressor cells in humans. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3818.
Endoluminal transgastric endoscopic anastomosis of the gallbladder using an anchoring self-expanding metal stent
Authors: K. Mönkemüller, M. Zabielski, A. Didowacz-Grollmann, C. von Gruchalla, H. Neumann, K. Vormbrock
Journal: Endoscopy (2013)

An 86-year-old woman with a history of diabetes mellitus type 2, hypertension, and coronary artery disease was admitted for acute cholecystitis. On presentation she had abdominal pain and fever. Physical examination was remarkable for epigastric and right upper quadrant tenderness. Laboratory data showed leukocytosis (16 000 cells/µL with left shift; normal range 4500 – 10 000 cells/µL). An abdominal ultrasound confirmed acute cholecystitis because of gallstone disease. The patient was started on intravenous ceftriaxone and metronidazole and she refused surgery repeatedly. Due to the risks of gallbladder hydrops or rupture, we drained the gallbladder endoscopically using a self-expandable metal prosthesis with two flanged ends (Axios, Xlumena, Mountain View, California, USA) ([Fig. 1]). This novel lumen-apposing stent has been previously used to drain pseudocysts and has provided excellent results when used for draining nonadherent extraintestinal fluid collections [1]. The patient underwent the procedure after five days of antibiotic therapy.
AB1189-HPR A Telephone Follow-Up after an Integrated Outpatient Osteoarthritis Intervention Does not Enhance Patient Health at 12 Months – Results from A Randomised Controlled Trial: Table 1.
Authors: R.H. Moe, M. Grotle, I. Kjeken, I.C. Olsen, P. Mowinckel, E.A. Haavardsholm, K.B. Hagen, T.K. Kvien, T. Uhlig
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Osteoarthritis (OA) is a frequent chronic musculoskeletal disorder. Patient education is a recommended core treatment, and telephone follow-up has been suggested to improve adherence. <h3>Objectives</h3> To examine the effect of a reminder telephone call on health status 4 months after an outpatient visit for patients with hand, hip, knee or generalized OA. <h3>Methods</h3> Patients with clinical OA had attended an integrated outpatient OA clinic and half of them an additional 3.5h multidisciplinary group based intervention. After 4 months, all patients were randomized to a 10 minutes telephone follow-up, or no such follow-up. Outcomes included pain, fatigue, and stiffness (NRS, 0-10), Western Ontario and McMaster- (WOMAC) (0-30, 0 is best) and Australian/Canadian (AUSCAN) (0-10, 0 is best) hand- (0-10, 0 is best) osteoarthritis indexes. Group differences were examined by mixed model analyses with random intercept, adjusted for baseline values. <h3>Results</h3> Of 390 patients, 86.4% (n=337) were women, and mean age (SD) was 63.1 (8.0) years. There were no significant differences in patient reported health status between the groups at 12 months followup. <h3>Conclusions</h3> A single telephone call follow-up at 4 month after a visit to an OA outpatient clinic did not impact patient reported health outcomes at 12 months. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5860
Abstract P1-14-05: Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer
Authors: B Aktas, S Kümmel, J Krocker, D Elling, T Lantzsch, J Bischoff, N Fersis, M Böhme, AK Belau, D Lampe, P Schmid
Journal: Cancer Research (2012)

Abstract Background: Several studies showed that pathologic complete response (pCR) is a surrogate for disease free survival (DFS) and overall survival (OS). Combinations of trastuzumab and anthracyclines in HER2-positive breast cancer are highly active but associated with a high incidence of cardiotoxicity. The risk of cardiac damage can be significantly reduced through liposomal encapsulation of anthracyclines. This phase I/II study was initiated to evaluate the combination of non-pegylated liposomal doxorubicin (NPLD), paclitaxel and lapatinib as primary treatment for patients with early stage, HER2-positive primary breast cancer. Patients and Methods: Patients with newly diagnosed HER2-positive (IHC 3+ or FISH+) early stage (T1c N1-2 or T2 N0-2) breast cancer were treated with NPLD (60mg/m2; day 1), paclitaxel (175mg/m2, day 1) and lapatinib (750–1500 mg orally daily) in 3-week intervals for up to 6 cycles. The primary endpoints were dose-limiting toxicities (DLT) and pathological complete response (pCR). Secondary endpoints include safety, incidence of cardiac events, and clinical response. Exploratory endpoints include molecular markers for sensitivity or resistance to chemotherapy and/or lapatinib evaluated. Results: A total of 84 patients have been included. No dose-limiting toxicity were observed and the maximum tolerated doses were NPLD 60mg/m2, paclitaxel 175mg/m2 and lapatinib 1500mg. Recommended phase 2 doses (P2D) were NPLD 60mg/m2, paclitaxel 175mg/m2 and lapatinib 1250mg. The treatment was generally well tolerated and associated with toxicities that were consistent with the known side-effects of the individual agents. No cardiac event has been observed to date. Preliminary efficacy data confirm a pCR breast rate of 41.7% and pCR rate in breast and lymph nodes of 37.5%, in 32 evaluable patients treated at ≥P2D. Conclusions: The combination of NPLD, paclitaxel and lapatinib is well tolerated and has high antitumor activity in patients with HER2-positive primary breast cancer. Updated results of all 84 patients will be presented. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-05.
Studies on the State of Insulin in Blood
Authors: Harry N. Antoniades, James A. Bougas, Hugh M. Pyle, Rafael Camerini-Davalos, Kare Gundersen
Journal: New England Journal of Medicine (1962)

EXPERIMENTAL studies, reported elsewhere, presented data on the relative amounts of "free" insulin and insulin complexes in the splenic, portal, hepatic and peripheral vein blood of diabetic and nondiabetic subjects.1 2 3 4 It was shown that insulin is secreted from the pancreas of both diabetic and nondiabetic subjects in the "free," biologically active form within minutes of intravenous administration of glucose.4 In the peripheral vein blood of nondiabetic subjects the insulin appeared both in the "free" form and as an inactive complex, the ratio depending on the metabolic state.2 3 4 In the fasting state the predominant form of insulin in blood circulated as . . .